Huakang Biomedical Holdings Co (HKSE:08622) Days Sales Outstanding : 128.89 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Days Sales Outstanding?

Huakang Biomedical Holdings Co's average Accounts Receivable for the three months ended in Dec. 2023 was HK$10.59 Mil. Huakang Biomedical Holdings Co's Revenue for the three months ended in Dec. 2023 was HK$7.50 Mil. Hence, Huakang Biomedical Holdings Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 128.89.

The historical rank and industry rank for Huakang Biomedical Holdings Co's Days Sales Outstanding or its related term are showing as below:

HKSE:08622' s Days Sales Outstanding Range Over the Past 10 Years
Min: 124.34 Med: 138.22 Max: 157.55
Current: 146.92

During the past 9 years, Huakang Biomedical Holdings Co's highest Days Sales Outstanding was 157.55. The lowest was 124.34. And the median was 138.22.

HKSE:08622's Days Sales Outstanding is ranked worse than
89.09% of 999 companies
in the Drug Manufacturers industry
Industry Median: 71.45 vs HKSE:08622: 146.92

Huakang Biomedical Holdings Co's Days Sales Outstanding declined from Dec. 2022 (131.34) to Dec. 2023 (128.89).

Huakang Biomedical Holdings Co Days Sales Outstanding Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Days Sales Outstanding Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

150.54

157.55

129.92

142.48

143.39

Huakang Biomedical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															131.34	147.05	168.49	155.32	128.89

Competitive Comparison of Huakang Biomedical Holdings Co's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Huakang Biomedical Holdings Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Huakang Biomedical Holdings Co's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huakang Biomedical Holdings Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Huakang Biomedical Holdings Co's Days Sales Outstanding falls into.

Huakang Biomedical Holdings Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Huakang Biomedical Holdings Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (10.575	+	10.591)	/	2 )	/	26.939	*	365
=	10.583					/	26.939	*	365
=	143.39

Huakang Biomedical Holdings Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	10.591)	/	1 )	/	7.498	*	365 / 4
=	10.591					/	7.498	*	365 / 4
=	128.89

Huakang Biomedical Holdings Co (HKSE:08622) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Huakang Biomedical Holdings Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co (HKSE:08622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

http://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Executives

Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Crystal Grant Limited	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co (HKSE:08622) Headlines

No Headlines